Puma Biotechnology, Inc. (PBYI) Stock Forecast
Data as of Sep 20, 2026Healthcare · Current price $9.60 (+0.79%)
Consensus Target
—
Upside
—
Analysts
1
Rating
Hold(3.00)
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
Consensus
Hold
Strong Buy0
Buy0
Hold1
Sell0
Strong Sell0
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
No analyst price targets available.
PBYI vs Sector & Market
| Metric | PBYI | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 3.00 | 2.25 | 2.42 |
| Analyst Count | 1 | 8 | 18 |
| Target Upside | — | +22217.1% | +21.5% |
| P/E Ratio | 15.74 | 3.75 | 38.34 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $61M | $61M | $61M | 1 |
| 2026-12-31 | $64M | $64M | $64M | 1 |
| 2027-12-31 | $218M | $218M | $218M | 1 |
| 2028-12-31 | $218M | $218M | $218M | 1 |
| 2029-12-31 | $217M | $217M | $217M | 1 |
| 2030-12-31 | $216M | $216M | $216M | 1 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $0.17 | $0.17 | $0.17 | 1 |
| 2026-12-31 | $0.21 | $0.21 | $0.21 | 1 |
| 2027-12-31 | $0.49 | $0.50 | $0.51 | 1 |
| 2028-12-31 | $0.45 | $0.45 | $0.45 | 1 |
| 2029-12-31 | $0.35 | $0.35 | $0.35 | 1 |
| 2030-12-31 | $0.20 | $0.20 | $0.20 | 1 |
Frequently Asked Questions
What is the analyst consensus for PBYI?
The consensus among 1 analysts covering Puma Biotechnology, Inc. (PBYI) is Hold with an average price target of N/A.
How many analysts cover PBYI?
1 analysts have issued ratings for Puma Biotechnology, Inc. in the past 12 months.
Is PBYI a buy or sell right now?
Based on 1 analyst ratings, PBYI has a consensus rating of Hold (3.00/5) with a N/A upside to the consensus target of N/A.
What are the earnings estimates for PBYI?
Analysts estimate PBYI will report EPS of $0.17 for the period ending 2026-09-30, with revenue estimated at $61M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.